Conditions: Diabetic Neuropathy, Painful
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 170
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and effectiveness of MK-6096 in the treatment of painful diabetic neuropathy (PDN) in adults.

Detailed description:

Arms:
arm 1: Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive MK-6096 10 mg once daily for 2 weeks during double-blind treatment period. arm 2: Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive placebo once daily for 2 weeks during double-blind treatment period.

Interventions: intervention 1: MK-6096 intervention 2: Placebo
Intervention descriptions: intervention 1: MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days. intervention 2: Matching compressed tablets, taken once daily at bedtime for 14 days.

Protocol document: